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Treatment of bovine pulmonary smooth muscle cells with U46619 inhibited the Na+/K+ ATPase activ-
ity in two parallel pathways: one of which is mediated via glutathionylation of the pump and the
other by augmenting the inhibitory activity of the 70 kDa inhibitor protein of Na+/K+ ATPase.
Although phospholemman deglutathionylates the pump leading to its activation, the inhibitor is
responsible for irreversible inhibition of Na+/K+ ATPase in an isoform speciﬁc manner during treat-
ment of the cells with U46619.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The Na+/K+ ATPase (NKA) is a ubiquitous plasma membrane
bound enzyme, generates transmembrane concentration gradients
for Na+ and K+ that are essential for the cells to function. The en-
zyme is composed of two essentially non-covalently linked sub-
units, viz., the a subunit, which is responsible for catalytic
activity of the pump; and the b subunit, which is necessary for
the stabilization and maturation as well as function of the pump
[1–3].
In recent time, the FXYD proteins, having the signature FXYD
motif in the N-terminal, are found to be novel regulators of NKA
[4,5]. At present, the FXYD family has at least 12 members. The
c-subunit of NKA is the only member in the FXYD family that
has two alternative splice variants (FXYD2a and FXYD2b) [5]. As
a family, FXYD proteins are found predominantly in tissues like
kidney, colon, pancreas, etc. (that are involved in solute and ﬂuid
transport) and also in electrically excitable tissues (heart, skeletal
muscle, etc.) [5]. Different protein kinase (s) can phosphorylate
the FXYD proteins due to presence of potential phosphorylation
sites onto their cytoplasmic tail [6–10]. An interesting ﬁnding fromour laboratory shows that PKA and PKC phosphorylate PLM
depending on its association with different isoforms of NKA [11].
Oxidative modiﬁcation can regulate protein functions. It may
provide an alternative to phosphorylation of the NKA or associated
FXYD because the pump’s subunits contain residues that can be
oxidized (e.g. the sulfhydryl group) [12] and it has been shown that
NKA in skeletal muscle is redox sensitive [13]. Bibert et al. [12] re-
cently showed that angiotensin II induces PKC activity and that
leads to ROS generation, which subsequently causes glutathionyla-
tion of the b subunit and hence inhibits NKA activity. On the other
hand, it has been shown that oxidant stress can also activates NKA
activity. A bolus of H2O2 activates NKA in cardiac myocytes [14].
The report from Bibert et al. [12] also seems interesting in that con-
text. They showed that although peroxynitrite inhibits the pump
by gulatathionylation of its b subunit, yet PLM relieved this inhibi-
tion by facilitating deglutathionylation of the pump.
Inhibition of NKA is known to be dependent upon its conforma-
tion. Ouabain has been shown to inhibit NKA activity by binding to
the E2 state of the enzyme [15]. Recently, we have reported a
70 kDa inhibitor protein of NKA in bovine pulmonary artery
smooth muscle (BPASM) that inhibits the pump upon binding to
its E1 site. We have also observed that the inhibitor showed higher
afﬁnity towards the a2 isoform of NKA than the a1 isoform [16].
In this present communication, we examined in BPASM cells
(BPASMCs), the regulation of NKA by the TxA2 mimetic U46619
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iﬁcation of the pump as we have previously reported that U46619
increases O2 generation via stimulation of NADPH oxidase activity
in BPASMCs [17]. Recently, we have reported the presence of PLM
in smooth muscle cells [11] and hence we investigated its involve-
ment in this scenario. Huang et al. [18] showed that different iso-
forms of NKA are differentially inhibited by oxidants. Since
BPASMCs contain both the a1 and a2 isoforms of NKA [11], there-
fore, one of our aims was to investigate the isoform speciﬁc regu-
lation of NKA by oxidants and to explore the underlying
mechanisms. In view of our recent report about the presence of a
70 kDa inhibitor of NKA [16], we also determined its role in regu-
lating the enzyme activity upon stimulation of the cells with
U46619.
2. Materials and methods
2.1. Materials
All the chemicals were the products of Sigma Chemical Co.
(USA) unless otherwise stated. NKA b1-subunit and a-subunit
(anti-LEAVE) speciﬁc polyclonal antibody was kindly provided by
Prof. Pablo Martin Vassalo, Department of Biochemistry and
Molecular Biology, University of La Lagune, La Lagune (Tenerife,
Spain) and by Prof. Tomas Pressley, Department of Physiology,
Texas Tech University Health Sciences Center [19]. Custom made
anti-PLM antibody was prepared according to Dey et al. [11].
2.2. Cell culture
BPASMCs were studied between passages 6 and 12. Cells were
maintained according to our previously described protocol [11].
2.3. Generation of antibody against the 70 kDa inhibitor protein of
NKA
Antibodies to puriﬁed inhibitor were raised in rabbit [20]. The
rabbit was injected subcutaneously as follows with the inhibitor
emulsiﬁed with Freund’s reagent (Freund’s complete adjuvant):
120 mg of inhibitor on day 1 and 100 mg on day 7. This was fol-
lowed by intramuscular injection of 20 mg of the inhibitor on days
28 and 35. Serum was collected on day 45 for afﬁnity puriﬁcation.
2.4. Reconstitution of NKA and PLM into liposomes
The puriﬁed fraction containing both the a1b1 and a2b1 iso-
zymes of NKA was reconstituted with or without PLM into the lip-
osomes which were prepared using the lipid DOPC by following
the procedure of Dey et al. [11]. Two other liposomal systems were
prepared which were reconstituted with PLM, 70 kDa inhibitor and
either with a1b1 or with a2b1 isozymes of NKA.
2.5. Na+ efﬂux through the NKA
NKA ﬂux in the reconstituted liposomes was determined as the
rate of pump-mediated [Na+]i decline by following the procedure
of Dey et al. [11].
2.6. Glutathionylation of NKA
To detect S-glutathionylation of the pump subunits, cells were
loaded with biotinylated GSH. After lysis, the membrane fraction
was isolated and the biotin-tagged glutathionylated subfraction
was precipitated using streptavidin–sepharose beads [21] and
immunoblotted for a and b1 NKA subunits. In separateexperiments the b1 subunit immunoprecipitated from the cell
membrane fraction was immunoblotted with an antibody against
glutathionylated protein (anti-GSH antibody, Invitrogen). When
indicated, the enzyme was exposed to 10 nM U46619 before bio-
tin-GSH ester was added at different time points. In vitro glutath-
ionylation was performed according to Passarelli et al. [22] with
1 mM GSH and 1 mM H2O2 and by using 0.05% Triton X 100 to per-
meate the liposomes.
To detect glutathionylation of the pump in its different confor-
mations, we used different buffer compositions to stabilize them.
For E1ATP: 0.1 mM EDTA, 25 mM histidine, 2 mM Na2ATP (pH
7.1); for E2: 0.1 mM EDTA, 25 mM histidine; for E1Na3: 100 mM
NaCl, 4 mM MgCl2, 20 mM histidine (pH 7.35).
2.7. Expression of 70 kDa protein
The level of 70 kDa inhibitor protein was measured in the cyto-
sol of BPASMCs by western blot study as previously described [11]
with polyclonal antibody against the said protein raised in rabbit.
2.8. Immunoﬂuorescence study
Cells were ﬁxed for the immunoﬂuorescence study according to
Santos et al. [23]. Antibody raised against the inhibitor protein was
used as primary antibody. FITC labeled anti-IgG was used as sec-
ondary antibody.
2.9. Measurement of ATPase activity
NKA activity was measured as previously described [11] with or
without U46619 treatment at different time points.
2.10. Statistical analysis
Data were analyzed by unpaired t test and analysis of variance,
followed by the test of least signiﬁcant differences for comparison
within and between the groups [24] (Daniel 1978). P < 0.05 was
considered signiﬁcant.
3. Results
3.1. Glutathionylation of NKA
We examined the identiﬁcation (Fig. 1A and B; lane 1) and
glutathionylation pattern (Fig. 1A and B; lanes 2 and 3) of differ-
ent subunits of NKA after treatment of BPASMCs with U46619.
Cells loaded with biotin-GSH were exposed to solutions contain-
ing 10 nM U46619 for 10 min. U46619 increased b1 subunit glu-
tathionylation detected by immunoblotting the glutathionylated
protein (GSS-protein) precipitated by streptavidin as shown in
Fig. 1B. The a1 subunit was not detected in the GSS-protein
sub fraction after oxidant treatment (Fig. 1A). To gain further
support for glutathionylation, we immunoprecipitated the b1
subunit and immunoblotted the precipitate with antibody
against GSS-protein. The reverse immunoprecipitation experi-
ment was also performed as shown in Fig. 1A and B (Lanes 4
and 5).
Cells treated with U46619 showed a large signal for glutath-
ionylation when the buffering condition stabilizes the E1 confor-
mation (Fig. 1C, lane 1 for E1ATP and lane 4 for E1Na3) whereas
the signal was much smaller in a solution that stabilizes the E2
conformation (Fig. 1C, lane 2) with the biotin-GSH technique. For
further conﬁrmation, cells were treated with 100 lM ouabain
and then with U46619. Glutathionylation was measured after
10 min. The signals for glutathionylation were also low in this case
Fig. 1. (A and B) Glutathionylation of a and b subunits of NKA in BPASMCs. Lane 1: Identiﬁcation of a and b1 subunit with anti-LEAVE and b1 subunit speciﬁc antibody in the
cell membrane fraction (50 lg of total protein). Lanes 2 and 3: Determination of glutathionylation pattern (by biotin-GSH technique) at basal and after U46619 treatment
conditions. It was found that only the b1 subunit is susceptible for glutathionylation after treatment with U46619. A similar result was found with GSH antibody technique
(lanes 4–5). (C) Glutathionylation pattern obtained when the pump was allowed to be stabilized in the E1 conformation (lane 1: E1ATP, lane 4: E1Na3 conformation) and in
the E2 conformation (lane 2). Lane 3: glutathionylation of the pump after treatment with ouabain. (D) Annexin II is used for loading control.
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bain stabilized the E2 conformation of the pump (Fig. 1C, lane 3).
3.2. Effect of U46619 on NKA activity and its glutathionylation level:
role of PLM and inhibitor protein
From western blot proﬁle it was found that U46619 treatment
increases the glutathionylation signal for both PLM and NKA b1
subunit (Fig. 2A and B, lanes 2 and 3). However, after 15–20 min,
glutathionylation of NKA goes on decreasing (Fig. 2B, lane 4)
although the expression levels of both the proteins remain same
(Fig. 2C and D). Similar results were also found by Bibert et al.
[12] in case of cardiac myocytes where they showed that FXYD
proteins facilitated the deglutathionylation of NKA and hence a
low glutathionylation signal was obtained. However, to ascertain
the role of PLM in this scenario, we performed studies with recon-
stituted liposomes. We used two different kinds of liposomal sys-
tems for this purpose: one of which was reconstituted with a1b1
and a2b1 isozymes of NKA and the other reconstituted with both
the a1b1 and a2b1 isozymes of NKA and PLM. No change in the glu-
tathionylation signal was observed in case of the liposomes recon-
stituted with a1b1 and a2b1 isozymes of NKA (Fig. 2E); while in
case of the liposomes reconstituted with both NKA (a1b1 and
a2b1 isoforms) and PLM, signal for b1-glutathionylation decreases
after 20 min (Fig. 2F, lane 3). These results indicated that PLM facil-
itated deglutathionylation of NKA. We next determined the role of
‘glutathionylation–deglutathionylation’ status of the pump on its
ATPase activity in the reconstituted liposomes. With decreasing le-
vel of glutathionylation, the ATPase activity of the pump increases
after 20 min of U46619 treatment (Fig. 3A vs. B). Interestingly, a
different observation was found with the pump activity in
BPASMCs. Cells treated with U46619 for 10 min decreases the ATP-
ase activity with increase in the glutathionylation level of the
pump (Fig. 3C, lane 2). But, deglutathionylation of the pump by
PLM after 20 min did not restore the basal pump activity (Fig. 3C,
lane 3) as observed in reconstituted liposomes, indicating an irre-
versible inhibition on the ATPase activity during oxidative stress.We found an increase in inhibitory activity of the 70 kDa protein,
which we have recently identiﬁed against the pump during
U46619 stimulation. To ascertain the role of the inhibitor protein
on the pump activity after U46619 treatment, cells were ﬁrst per-
meabilised with 0.01% (v/v) Triton X-100 in PBS for 15 min at room
temperature. This treatment restores the normal morphological
integrity of the cells as suggested by Santos et al. [23]. Next the
cells were loaded with polyclonal antibody against the inhibitor
followed by treatment with U46619 (10 nM) and after 20 min
the pump activity was measured. Blocking the inhibitor activity
of the 70 kDa protein with its antibody showed that the pump
activity was greater compared to that observed without the anti-
body pretreatment (Fig. 3C, lane 4) and after 40 min, it almost
reaches the basal value (Fig. 3C, lane 5). However, from western
blot proﬁle (Fig. 4A), it was observed that the expression level of
the inhibitor protein was not altered during oxidative stress caused
by U46619 (Fig. 4A). The binding of the antibody to the inhibitor
protein was conﬁrmed by immunoﬂuorescence study (Fig. 4B).
To investigate the role of the 70 kDa inhibitor on different iso-
forms of NKA under oxidative stress, we performed in vitro glu-
tathionylation and measured the ATPase activity in the liposomes
reconstituted with different isozymes of NKA (either a1b1 or
a2b1) in conjugation with PLM and the 70 kDa inhibitor protein.
Measurement of ATPase activity (Fig. 3D vs. E) clearly showed that
under oxidative stress the inhibitor inhibited the a2b1 isozyme
more than the a1b1 isozyme of NKA.
3.3. Role of NADPH oxidase
It was observed that only the b subunit of the pump is suscep-
tible to glutathionylation when the cells were treated with
U46619. Moreover, the U46619 induced glutathionylation was
abolished by pre incubating the cells with SQ29584 (TxA2 receptor
antagonist: 1 lM), SOD (O2 scavenger: 200 lM) and ebselen
(ONOO scavenger: 1 lM) for 5 min (Fig. 5). These results clearly
indicated that U46619 glutathionylate the pump in NADPH oxidase
dependent mechanism.
Fig. 2. Identiﬁcation of glutaredoxin1 and time dependent glutathionylation (with anti-GSH antibody technique) of PLM as well as NKA (50 lg of total protein was loaded
onto the wells). (A) Lane 1: Identiﬁcation of PLM in the cell membrane of BPASMCs; lanes 2–4: glutathionylation pattern of PLM at basal, after 10 min and after 20 min of
U46619 treatment, respectively. (B) Lane 1: Identiﬁcation of GRX1 in the cell membrane of BPASMCs; lanes 2–4: glutathionylation pattern of NKA at basal, after 10 min and
after 20 min of U46619 treatment, respectively. (C and D) Represent the protein expression proﬁle of PLM and NKA. Glutathionylation of NKA (a1b1 and a2b1 isoforms) alone
(E) and in presence of PLM (F) in reconstituted liposomes; lane 1: glutathionylation under basal condition; lanes 2 and 3: glutathionylation after 10 and 20 min, respectively.
(G) Annexin II is used for loading control.
Fig. 3. Change of NKA activity in reconstituted liposomes and in BPASMCs. (A and B) Proteoliposomes reconstituted with NKA (a1b1 and a2b1 isoforms) alone and in
conjugation with PLM: lanes 1 and 2, ATPase activity at basal and after 20 min of U46619 treatment, respectively. (C) ATPase activity in BPASMCs: lanes 1–3, ATPase activity
at basal condition, after 10 min and after 20 min of U46619 treatment, respectively; lanes 4 and 5, ATPase activity after 20 min and 40 min of U46619 treatment in presence of
antibody against the 70 kDa inhibitor of NKA. (D and E) Proteoliposomes reconstituted with either a1b1 or a2b1 isozyme of NKA along with PLM and 70 kDa inhibitor,
respectively: lanes 1 and 2, ATPase activity at basal and after 20 min of U46619 treatment. Results are mean ± SE (n = 4). aP < 0.05 compared to basal condition; bP < 0.05
compared to lane 4.
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Fig. 4. Expression of 70 kDa inhibitor protein in the cytosol of BPASMCs (30 lg of total protein was loaded onto the wells). (A) Western blot study: lanes 1–3, untreated cells,
after 10 min and after 20 min of treatment with U46619, respectively. (B) b-Actin is used as a loading control. (C) Immunoﬂuorescence study using FITC conjugated anti-
70 kDa inhibitor antibody.
Fig. 5. Role of NADPH oxidase on the glutathionylation level of Na+/K+ ATPase (50 lg of total protein was loaded onto the wells). (A) Lane 1: Basal glutathionylation. Lane 2:
Glutathionylation after 10 min of U46619 treatment. Lanes 3–5: Glutathionylation pattern after preincubating the cells with SQ 29548, SOD and with ebselen, respectively.
(B) b-Actin is used as a loading control.
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In this communication, we examined the regulation of NKA dur-
ing stimulation of BPASMCs with the TxA2 mimetic, U46619. We
also examined the role of PLM in this scenario. Interestingly, we
observed an important role of the 70 kDa inhibitor protein towards
the irreversible inhibition of NKA under U46619 mediated oxida-
tive stress.
The origin of ROS in the vessel wall is currently of immense
interest, because accumulating evidence suggests that these mole-
cules participate in the pathogenesis of vascular diseases [25]. We
have recently demonstrated that NADPH oxidase is a major source
of ROS in vascular smooth muscle cells [17]. White et al. [26] dem-
onstrated that angiotensin II by producing ONOO inhibits the NKA
activity due to glutathionylation of b subunit of the pump in a
NADPH oxidase dependent manner.
We found that only the b subunit (speciﬁcally the b1 subunit) of
the pump was susceptible to glutathionylation when the cells were
treated with U46619 and it was interesting to note that this glu-
tathionylation of NKA was conformation dependent. Glutathiony-
lation inhibits the pump by stabilizing its E1 conformation.
Figtree et al. [27] showed that glutathionylation of NKA is revers-
ible in nature where glutaredoxin1 (GRX1) facilitated deglutath-
ionylation of the pump. In BPASMCs, we determined the
presence of GRX1 (Fig. 2B, lane 1), but the expected glutathionyla-
tion signal was quite different after its inhibition. Bibert et al. [12]
showed that recombinant FXYD3 facilitated the deglutathionyla-
tion of NKA in Xenopus oocytes. We found that glutathionylation
of PLM was induced from baseline by exposing the cells to
U46619. We also found that after 20 min of U46619 treatment,
the signal for glutathionylation of NKA decreases considerably.
We propose that there might be two possibilities to explain theseresults: either PLM facilitates the deglutathionylation of NKA or
GRX1 might have a contribution. Again if GRX1 was involved, then
its inhibition might prevent the loss of glutathionylation signal of
NKA. But, we did not ﬁnd any discernible contribution from
GRX1 during the oxidative stress in the cells (Fig. 2B, lane 4), which
clearly suggest the possibility that GRX1 might be inhibited under
this condition. Inhibition of GRX1 under oxidative stress has also
been suggested by Heshemy et al. [28]. To ascertain the role of
PLM in this scenario, we performed studies with liposomes recon-
stituted with NKA (a1b1 and a2b1 isozymes) and PLM. No change in
the glutathionylation signal was observed after 30 min of U46619
treatment in case of the liposomes reconstituted with a1b1 and
a2b1 isozymes of NKA. However, results obtained from the lipo-
somes reconstituted with both PLM and NKA (a1b1 and a2b1 iso-
zyme) were different. It clearly suggests that PLM facilitated
deglutathionylation of NKA b1 subunit. A similar result was also
found from ATPase activity measurement in reconstituted
liposomes.
Although PLM deglutathionylates the b1 subunit of NKA, yet
measurement of ATPase activity in the cells did not corroborate
with the results obtained from liposomes reconstituted with either
a1b1 or a2b1 isozymes NKA and PLM. Bibert et al. [12] showed that
the ATPase activity was proportional with the level of glutathiony-
lation of the pump, but we have not found such proportionality
after treatment of the cells with U46619. It is also well established
that oxidant stress during ischemic condition may cause accumu-
lation of substances that inhibit membrane transporter such as
NKA. Fuller et al. [29] showed that an unstable cardiac and
brain-speciﬁc inhibitor of the NKA, whose production is linked to
oxidant stress, accumulates intracellularly during ischemia. Here
in case of BPASMCs, we found an increase in the activity of
70 kDa inhibitor protein towards NKA after 20 min of U46619
3540 K. Dey et al. / FEBS Letters 587 (2013) 3535–3540treatment without any change in the expression level of the
protein.
The mechanism of U46619 induced increase in the inhibitor
activity of the 70 kDa protein in the cells is currently unknown.
Conceivably, in BPASMCs, two mechanisms were simultaneous
operating in inhibiting NKA by producing ONOO in NADPH oxi-
dase dependent manner under U46619 treatment to the cells.
One operated through glutathionylation of the pump, while the
other appears to occur via the inhibitor protein. These two path-
ways were linked with a common mechanism. Glutathionylation
inhibit the pump by stabilizing its E1 conformation, and the inhib-
itor binds with the pump in the same conformation. Apparently,
this may explain the irreversible inhibition of NKA activity under
oxidant stress by U46619 even in presence of PLM. This result
although contradicts the work of Figtree et al. [26], but oxidant
mediated irreversible inhibition of the pump was also reported
by Huang et al. [30]. Interestingly, functional inhibition of the
70 kDa inhibitor with its polyclonal antibody restores the basal
ATPase activity. Deactivation of the inhibitor protein due to bind-
ing of the antibody was conﬁrmed by immunoﬂuorescence study.
Huang et al. [18] showed that the a2 and a3 isoforms are more sus-
ceptible than the a1 isoform toward oxidants. In BPASMCs, oxidant
induce the inhibitory activity of the 70 kDa inhibitor protein,
which have different afﬁnities toward different isoforms of NKA
(a2 isoform is more susceptible than a1) resulting in the differen-
tial regulation of the NKA isoforms.
5. Conclusion
Our present study suggests that in addition to the inhibition of
NKA through glutathionylation, a marked increase in the inhibition
of the enzyme occurs via activation of the 70 kDa inhibitor protein
under U46619 stimulation to the cells. We also suggest that the
presence of this inhibitor is solely responsible for isoform speciﬁc
irreversible inhibition of NKA by oxidants during U46619 stimula-
tion of the cells.
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